Novartis Pharmaceuticals
Basel, Switzerland
NCT Number: NCT00246584
This study will evaluate the safety and efficacy of long term treatment of SPP100 in patients with essential hypertension. (Trial is not recruiting in the US)
Looking for future studies?
Notify Me20 year–80 year
All sexes
Interventional
Phase 2
Basel, Switzerland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Looking for future studies?
Notify MeNovartis
Industry
Long-Term Treatment, Multicenter, Open-Label Study With SPP100 in Patients With Essential Hypertension
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07833384
Arterial Occlusive Diseases, Arteriosclerosis
Baton Rouge, Louisiana, United States
View Trial DetailsNCT06689930
Blood Pressure, Cardiovascular Diseases
Madison, Wisconsin, United States
View Trial DetailsNCT02290392
Cardiovascular Diseases, Hypertension
Bethesda, Maryland, United States
View Trial DetailsNCT00837122
Cardiovascular Diseases, Diabetes
Accra, Ghana
View Trial Details